ACELRX PHARMACEUTICALS AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx is currently focused on the development of products for the treatment of moderate-to-severe acute pain based on the company’s proprietary sublingual formulation technology. For more information, please select a product below. DSUVIA™ (in US) Pre-Clinical. Phase
1.
INVESTOR RELATIONS
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. 3 Mo. 6 Mo. 1 Yr. Data provided by Nasdaq. Minimum 15 minutes delayed. ACELRX ANNOUNCES PRICING OF $27.5 MILLION PUBLIC OFFERING REDWOOD CITY, Calif., Jan. 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN We are looking to add highly skilled and dynamic individuals to our team who are passionate about improving the lives of patients with acute pain. We offer competitive compensation and benefits, and we recognize outstanding performance. AcelRx Pharmaceuticals is proud to be an equal opportunity employer & prohibits unlawful discrimination based
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Moderate-to-Severe Acute Pain in a Hospital Setting Moderate-to-severe acute pain management in the hospital remains a challenge for healthcare providers with up to 75% of patients reporting inadequate pain relief following surgery 1.Approximately 12 million surgical procedures per year result in moderate-to-severe acute pain in the U.S. 2, with an additional 7.4 million hospital inpatients in ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Zalviso is a drug/device combination product designed to deliver 15 mcg sufentanil, a high therapeutic index opioid, formulated in a proprietary noninvasive sublingual dosage form via a novel hand-held, pre-programmed, patient-controlled analgesia system. 5. Zalviso has the potential to address several key disadvantages of IV PCA, including:
PAMELA P. PALMER, MD, PHD Dr. Palmer has dedicated her career to researching and treating pain, first as an anesthesiologist at UCSF and in her current role as chief medical officer and a member of the board of directors of AcelRx, a company she co-founded in July 2005. Dr. Palmer gained extensive experience in the treatment of pain during her tenure as the director of
COST OF INTRAVENEOUS PATIENT CONTROLLED ANALGESIA … Xiang (Jay) Ji, MS1, Jennifer Stephens, PharmD1, Pamela Palmer, MD, PhD2 1Pharmerit International, Bethesda, MD, USA; 2AcelRx Pharmaceuticals, Inc, Redwood City, CA, USA COST OF INTRAVENEOUS PATIENT ‐CONTROLLED ANALGESIA (IV PCA) EQUIPMENT AND OPIOID MEDICATION FOR ORTHOPEDIC AND ABDOMINAL SURGERIES IN US HOSPITALS ACELRX PHARMACEUTICALS AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx is currently focused on the development of products for the treatment of moderate-to-severe acute pain based on the company’s proprietary sublingual formulation technology. For more information, please select a product below. DSUVIA™ (in US) Pre-Clinical. Phase 1.
INVESTOR RELATIONS
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. 3 Mo. 6 Mo. 1 Yr. Data provided by Nasdaq. Minimum 15 minutes delayed. ACELRX ANNOUNCES PRICING OF $27.5 MILLION PUBLIC OFFERING REDWOOD CITY, Calif., Jan. 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN We are looking to add highly skilled and dynamic individuals to our team who are passionate about improving the lives of patients with acute pain. We offer competitive compensation and benefits, and we recognize outstanding performance. AcelRx Pharmaceuticals is proud to be an equal opportunity employer & prohibits unlawful discrimination based
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Moderate-to-Severe Acute Pain in a Hospital Setting Moderate-to-severe acute pain management in the hospital remains a challenge for healthcare providers with up to 75% of patients reporting inadequate pain relief following surgery 1.Approximately 12 million surgical procedures per year result in moderate-to-severe acute pain in the U.S. 2, with an additional 7.4 million hospital inpatients in ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Zalviso is a drug/device combination product designed to deliver 15 mcg sufentanil, a high therapeutic index opioid, formulated in a proprietary noninvasive sublingual dosage form via a novel hand-held, pre-programmed, patient-controlled analgesia system. 5. Zalviso has the potential to address several key disadvantages of IV PCA, including:
PAMELA P. PALMER, MD, PHD Dr. Palmer has dedicated her career to researching and treating pain, first as an anesthesiologist at UCSF and in her current role as chief medical officer and a member of the board of directors of AcelRx, a company she co-founded in July 2005. Dr. Palmer gained extensive experience in the treatment of pain during her tenure as the director of
COST OF INTRAVENEOUS PATIENT CONTROLLED ANALGESIA … Xiang (Jay) Ji, MS1, Jennifer Stephens, PharmD1, Pamela Palmer, MD, PhD2 1Pharmerit International, Bethesda, MD, USA; 2AcelRx Pharmaceuticals, Inc, Redwood City, CA, USA COST OF INTRAVENEOUS PATIENT ‐CONTROLLED ANALGESIA (IV PCA) EQUIPMENT AND OPIOID MEDICATION FOR ORTHOPEDIC AND ABDOMINAL SURGERIES IN US HOSPITALS ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx | Innovative Therapies for Acute Pain. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. For more information, please select a product below.
ACELRX PHARMACEUTICALS TO ACQUIRE TETRAPHASE REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) ACELRX PHARMACEUTICALS, INC : PUBLICATIONS Title: American Society of Anesthesiologists, October 2013: A Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab® PCA System/15mcg Plus Rescue Morphine vs. Placebo Plus Rescue Morphine in Patients with Moderate ACELRX PHARMACEUTICALS, INC : SUFENTANIL AcelRx Pharmaceuticals, Inc : Sufentanil. NanoTab™. Sufentanil. Publications. Sufentanil is a strong opioid analgesic currently marketed for IV and epidural anesthesia. There has been published evidence that sufentanil has an analgesic effect, however, its use has been limited due to its short duration of action when delivered intravenously.
ACELRX PHARMACEUTICALS, INC : NANOTAB™ TECHNOLOGY AcelRx's proprietary NanoTab® technology is a non-invasive, sublingual dosage form that efficiently delivers highly lipophilic drugs with consistent pharmacokinetics. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Sufentanil Sufentanil is an opioid analgesic currently marketed for IV and epidural anesthesia and analgesia; however, its postoperative use has been limited due to its short duration of action when delivered intravenously. 1 The pharmaceutical attributes of sufentanil, including lipid solubility and degree of non-ionization, result in rapid cell membrane penetration allowing entry into the ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Moderate-to-Severe Acute Pain in a Hospital Setting Moderate-to-severe acute pain management in the hospital remains a challenge for healthcare providers with up to 75% of patients reporting inadequate pain relief following surgery 1.Approximately 12 million surgical procedures per year result in moderate-to-severe acute pain in the U.S. 2, with an additional 7.4 million hospital inpatients in VINCENT J. ANGOTTI
Chief Executive Officer Mr. Angotti was appointed chief executive officer and a member of the company's board of directors in March 2017. Mr. Angotti brings over two decades of experience leading executive and commercial teams at public and private life sciences companies, most recently as CEO of XenoPort, Inc., a biopharmaceutical company focused on the development of treatments for ACELRX ANNOUNCES FDA APPROVAL OF DSUVIA™ AcelRx will host a conference call Monday, November 5th at 8:30 a.m. Eastern Time to discuss the FDA approval of DSUVIA. The call can be accessed by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. The call will also be webcast live on the Company's website at www
ACELRX PHARMACEUTICALS RECEIVES $65 MILLION FROM THE REDWOOD CITY, Calif., Sept. 21, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil ACELRX PHARMACEUTICALS AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx | Innovative Therapies for Acute Pain. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. For more information, please select a product below.
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN DSUVIA (sufentanil sublingual tablet, 30 mcg) DSUVIA is designed to provide a non-invasive treatment option for patients with moderate-to-severe acute pain, in multiple medically supervised settings ranging from the battlefield, civilian emergency departments, ambulatory surgery centers, and hospitals. INVESTOR RELATIONS
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. 3 Mo. 6 Mo. 1 Yr. Data provided by Nasdaq. Minimum 15 minutes delayed. ACELRX ANNOUNCES PRICING OF $27.5 MILLION PUBLIC OFFERING REDWOOD CITY, Calif., Jan. 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx | Innovative Therapies for Acute Pain. AcelRx welcomes inquiries from members of the media and will respond in a timely manner whenever possible. You can reach us at info@acelrx.com. Please note, this contact information is for use by media professionals only. If you are not a media professional (reporter, editor, blogger, producer
ACELRX PHARMACEUTICALS, INC : PUBLICATIONS Title: American Society of Anesthesiologists, October 2013: A Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab® PCA System/15mcg Plus Rescue Morphine vs. Placebo Plus Rescue Morphine in Patients with Moderate ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Zalviso is a drug/device combination product designed to deliver 15 mcg sufentanil, a high therapeutic index opioid, formulated in a proprietary noninvasive sublingual dosage form via a novel hand-held, pre-programmed, patient-controlled analgesia system. 5. Zalviso has the potential to address several key disadvantages of IV PCA, including:
PAMELA P. PALMER, MD, PHD Dr. Palmer has dedicated her career to researching and treating pain, first as an anesthesiologist at UCSF and in her current role as chief medical officer and a member of the board of directors of AcelRx, a company she co-founded in July 2005. Dr. Palmer gained extensive experience in the treatment of pain during her tenure as the director of
ACELRX PHARMACEUTICALS RECEIVES $65 MILLION FROM THE REDWOOD CITY, Calif., Sept. 21, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil ACELRX PHARMACEUTICALS AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx | Innovative Therapies for Acute Pain. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. For more information, please select a product below.
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN DSUVIA (sufentanil sublingual tablet, 30 mcg) DSUVIA is designed to provide a non-invasive treatment option for patients with moderate-to-severe acute pain, in multiple medically supervised settings ranging from the battlefield, civilian emergency departments, ambulatory surgery centers, and hospitals. INVESTOR RELATIONS
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. 3 Mo. 6 Mo. 1 Yr. Data provided by Nasdaq. Minimum 15 minutes delayed. ACELRX ANNOUNCES PRICING OF $27.5 MILLION PUBLIC OFFERING REDWOOD CITY, Calif., Jan. 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx | Innovative Therapies for Acute Pain. AcelRx welcomes inquiries from members of the media and will respond in a timely manner whenever possible. You can reach us at info@acelrx.com. Please note, this contact information is for use by media professionals only. If you are not a media professional (reporter, editor, blogger, producer
ACELRX PHARMACEUTICALS, INC : PUBLICATIONS Title: American Society of Anesthesiologists, October 2013: A Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab® PCA System/15mcg Plus Rescue Morphine vs. Placebo Plus Rescue Morphine in Patients with Moderate ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Zalviso is a drug/device combination product designed to deliver 15 mcg sufentanil, a high therapeutic index opioid, formulated in a proprietary noninvasive sublingual dosage form via a novel hand-held, pre-programmed, patient-controlled analgesia system. 5. Zalviso has the potential to address several key disadvantages of IV PCA, including:
PAMELA P. PALMER, MD, PHD Dr. Palmer has dedicated her career to researching and treating pain, first as an anesthesiologist at UCSF and in her current role as chief medical officer and a member of the board of directors of AcelRx, a company she co-founded in July 2005. Dr. Palmer gained extensive experience in the treatment of pain during her tenure as the director of
ACELRX PHARMACEUTICALS RECEIVES $65 MILLION FROM THE REDWOOD CITY, Calif., Sept. 21, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil ACELRX PHARMACEUTICALS ANNOUNCES PUBLICATION OF CLINICAL REDWOOD CITY, Calif., Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study entitled "Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX PHARMACEUTICALS, INC : NANOTAB™ TECHNOLOGY AcelRx's proprietary NanoTab® technology is a non-invasive, sublingual dosage form that efficiently delivers highly lipophilic drugs with consistent pharmacokinetics. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN DZUVEO (known as DSUVIA™ in the US) is a sublingual sufentanil tablet (30 mcg) delivered via a disposable, prefilled, single-dose applicator. The product is designed to be administered by a healthcare provider for the management of moderate-to-severe acute pain in a variety of medically monitored settings, including emergency medicine ACELRX PHARMACEUTICALS, INC : SUFENTANIL AcelRx Pharmaceuticals, Inc : Sufentanil. NanoTab™. Sufentanil. Publications. Sufentanil is a strong opioid analgesic currently marketed for IV and epidural anesthesia. There has been published evidence that sufentanil has an analgesic effect, however, its use has been limited due to its short duration of action when delivered intravenously.
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN We are looking to add highly skilled and dynamic individuals to our team who are passionate about improving the lives of patients with acute pain. We offer competitive compensation and benefits, and we recognize outstanding performance. AcelRx Pharmaceuticals is proud to be an equal opportunity employer & prohibits unlawful discrimination based
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Sufentanil Sufentanil is an opioid analgesic currently marketed for IV and epidural anesthesia and analgesia; however, its postoperative use has been limited due to its short duration of action when delivered intravenously. 1 The pharmaceutical attributes of sufentanil, including lipid solubility and degree of non-ionization, result in rapid cell membrane penetration allowing entry into the ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Moderate-to-Severe Acute Pain in a Hospital Setting Moderate-to-severe acute pain management in the hospital remains a challenge for healthcare providers with up to 75% of patients reporting inadequate pain relief following surgery 1.Approximately 12 million surgical procedures per year result in moderate-to-severe acute pain in the U.S. 2, with an additional 7.4 million hospital inpatients in CORPORATE GOVERNANCE GUIDELINES Corporate Governance Guidelines. Adopted: October 30, 2019. The Board of Directors (the “ Board ”) of AcelRx Pharmaceuticals, Inc. (“ AcelRx ”, or the “ Company ”) has adopted the Corporate Governance Guidelines (the “ G uidelines ”) below to assist the Board in serving the best interests of the Company and its stockholders.
ACELRX PHARMACEUTICALS RECEIVES $65 MILLION FROM THE REDWOOD CITY, Calif., Sept. 21, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil ACELRX PHARMACEUTICALS AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx | Innovative Therapies for Acute Pain. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. For more information, please select a product below.
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx is currently focused on the development of products for the treatment of moderate-to-severe acute pain based on the company’s proprietary sublingual formulation technology. For more information, please select a product below. DSUVIA™ (in US) Pre-Clinical. Phase 1.
INVESTOR RELATIONS
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. 3 Mo. 6 Mo. 1 Yr. Data provided by Nasdaq. Minimum 15 minutes delayed. ACELRX ANNOUNCES PRICING OF $27.5 MILLION PUBLIC OFFERING REDWOOD CITY, Calif., Jan. 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of
ACELRX PHARMACEUTICALS ANNOUNCES PUBLICATION OF CLINICAL REDWOOD CITY, Calif., Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study entitled "Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative ACELRX PHARMACEUTICALS TO ACQUIRE TETRAPHASE REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAINACELRX JOBSACELRX PHARMAACELRX PHARMACEUTICALS EARNINGS DATEACELRX PHARMACEUTICALS FDAACELRX PHARMACEUTICALS INCACELRX PHARMACEUTICALS NEWS Moderate-to-Severe Acute Pain in a Hospital Setting Moderate-to-severe acute pain management in the hospital remains a challenge for healthcare providers with up to 75% of patients reporting inadequate pain relief following surgery 1.Approximately 12 million surgical procedures per year result in moderate-to-severe acute pain in the U.S. 2, with an additional 7.4 million hospital inpatients in ACELRX PHARMACEUTICALS RECEIVES $65 MILLION FROM THE REDWOOD CITY, Calif., Sept. 21, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil SUBLINGUAL SUFENTANIL, AN “IDEAL” OPIOID FOR ACUTE AND Tong-Joo Gan, MD MHS1; Pamela P. Palmer, MD PhD2,3; Mike A. Royal, MD JD3 1Duke University Medical Center, Durham, NC; 2University of California, San Francisco, San Francisco, CA 3AcelRx Pharmaceuticals, Redwood City, CA Sublingual Sufentanil, an “Ideal” Opioid for Acute and Breakthrough Pain: The Clinical Importance of CST ½ and t ke0 Results
ACELRX PHARMACEUTICALS AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx | Innovative Therapies for Acute Pain. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. For more information, please select a product below.
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx is currently focused on the development of products for the treatment of moderate-to-severe acute pain based on the company’s proprietary sublingual formulation technology. For more information, please select a product below. DSUVIA™ (in US) Pre-Clinical. Phase 1.
INVESTOR RELATIONS
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. 3 Mo. 6 Mo. 1 Yr. Data provided by Nasdaq. Minimum 15 minutes delayed. ACELRX ANNOUNCES PRICING OF $27.5 MILLION PUBLIC OFFERING REDWOOD CITY, Calif., Jan. 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of
ACELRX PHARMACEUTICALS ANNOUNCES PUBLICATION OF CLINICAL REDWOOD CITY, Calif., Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study entitled "Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative ACELRX PHARMACEUTICALS TO ACQUIRE TETRAPHASE REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAINACELRX JOBSACELRX PHARMAACELRX PHARMACEUTICALS EARNINGS DATEACELRX PHARMACEUTICALS FDAACELRX PHARMACEUTICALS INCACELRX PHARMACEUTICALS NEWS Moderate-to-Severe Acute Pain in a Hospital Setting Moderate-to-severe acute pain management in the hospital remains a challenge for healthcare providers with up to 75% of patients reporting inadequate pain relief following surgery 1.Approximately 12 million surgical procedures per year result in moderate-to-severe acute pain in the U.S. 2, with an additional 7.4 million hospital inpatients in ACELRX PHARMACEUTICALS RECEIVES $65 MILLION FROM THE REDWOOD CITY, Calif., Sept. 21, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil SUBLINGUAL SUFENTANIL, AN “IDEAL” OPIOID FOR ACUTE AND Tong-Joo Gan, MD MHS1; Pamela P. Palmer, MD PhD2,3; Mike A. Royal, MD JD3 1Duke University Medical Center, Durham, NC; 2University of California, San Francisco, San Francisco, CA 3AcelRx Pharmaceuticals, Redwood City, CA Sublingual Sufentanil, an “Ideal” Opioid for Acute and Breakthrough Pain: The Clinical Importance of CST ½ and t ke0 Results
ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx | Innovative Therapies for Acute Pain. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. For more information, please select a product below.
ACELRX PHARMACEUTICALS TO ACQUIRE TETRAPHASE REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. ACELRX PHARMACEUTICALS ANNOUNCES REVISED MERGER AGREEMENT REDWOOD CITY, Calif., May 27, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of an amendment to its merger agreement to acquire Tetraphase Pharmaceuticals, Inc. ACELRX PHARMACEUTICALS, INC : SUFENTANIL AcelRx Pharmaceuticals, Inc : Sufentanil. NanoTab™. Sufentanil. Publications. Sufentanil is a strong opioid analgesic currently marketed for IV and epidural anesthesia. There has been published evidence that sufentanil has an analgesic effect, however, its use has been limited due to its short duration of action when delivered intravenously.
ACELRX PHARMACEUTICALS, INC : NANOTAB™ TECHNOLOGY AcelRx's proprietary NanoTab® technology is a non-invasive, sublingual dosage form that efficiently delivers highly lipophilic drugs with consistent pharmacokinetics. NEWS RELEASES
AcelRx Pharmaceuticals to Host Analyst & Investor Event on December 1, 2016. - Expert panel to discuss market opportunity in emergency medicine for investigational agent ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain REDWOOD CITY, Calif. , Nov. 9, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. ACELRX | INNOVATIVE THERAPIES FOR ACUTE PAIN Zalviso is a drug/device combination product designed to deliver 15 mcg sufentanil, a high therapeutic index opioid, formulated in a proprietary noninvasive sublingual dosage form via a novel hand-held, pre-programmed, patient-controlled analgesia system. 5. Zalviso has the potential to address several key disadvantages of IV PCA, including:
RAFFI ASADORIAN
Mr. Asadorian was appointed chief financial officer in August 2017. Mr. Asadorian brings over 25 years of finance, strategy and corporate development experience to AcelRx. Prior to joining AcelRx, Mr. Asadorian served as the Chief Financial Officer of Amyris, Inc., a publicly traded commercial-stage biotechnology company, from 2015-2017.
ACELRX ANNOUNCES FDA APPROVAL OF DSUVIA™ AcelRx will host a conference call Monday, November 5th at 8:30 a.m. Eastern Time to discuss the FDA approval of DSUVIA. The call can be accessed by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. The call will also be webcast live on the Company's website at www
Toggle navigation
* Careers
* Contact
* Company
* Founder's Story
* Senior Management
* Board of Directors * Products
* Overview
* SUFENTANIL
* DSUVIA
* DZUVEO
* Zalviso US
* Zalviso EU
* Partnering
* Investors
* Media
* Press Releases
* Publications
* Military
* Careers
* Contact
SIMPLIFYING
ACUTE PAIN
RELIEF
THE STORY BEHIND
ACELRX
Pamela Palmer, MD, PhD, envisioned a different way to treat moderate-to-severe acute pain. Learn what inspired the AcelRx cofounder to develop a novel noninvasive technology. Read the story »
COVID-19 UPDATE
If your hospital is facing an IV opioid shortage during the COVID-19 pandemic, AcelRx may be able to provide assistance. Please read the letter from Dr. Palmer to learn more about this option. Read the letter »
Pamela Palmer, MD, PhD, envisioned a different way to treat moderate-to-severe acute pain. Learn what inspired the AcelRx cofounder to develop a novel noninvasive technology. Read the story »
COVID-19 UPDATE
If your hospital is facing an IV opioid shortage during the COVID-19 pandemic, AcelRx may be able to provide assistance. Please read the letter from Dr. Palmer to learn more about this option. Read the letter »
ABOUT ACELRX
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. FDA-APPROVED
Please see DSUVIA Important Safety Information, including BOXED WARNING, and full Prescribing Information .
visit dsuvia.com »
PROPRIETARY SUBLINGUAL TECHNOLOGY DSUVIA® was developed using this proprietary sublingual technology. __Learn More
2020 AcelRx Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy | Terms of Use | CA state requirements NP-US-NP-0002 04/20 
